Krystal Biotech (KRYS) Current Assets (2016 - 2026)

Krystal Biotech (KRYS) has 11 years of Current Assets data on file, last reported at $1.0 billion in Q1 2026.

• For the quarter ending Q1 2026, Current Assets rose 32.99% year-over-year to $1.0 billion; the trailing twelve-month figure through Mar 2026 stood at $1.0 billion (up 32.99% YoY), and the FY2025 full-year result was $1.0 billion, up 38.08% from the prior year.
• Current Assets steadied at $1.0 billion in Q1 2026, from $1.0 billion in the prior quarter.
• In the past five years, Current Assets ranged from a high of $1.0 billion in Q4 2025 to a low of $355.4 million in Q1 2023.
• A 5-year average of $645.6 million and a median of $602.2 million in 2024 frame the typical range for Current Assets.
• Across the five-year window, Current Assets slipped 18.85% in 2023 and soared 69.44% in 2024, its largest moves.
• Tracing KRYS's Current Assets over 5 years: stood at $383.8 million in 2022, then soared by 53.19% to $587.9 million in 2023, then rose by 26.22% to $742.0 million in 2024, then jumped by 38.08% to $1.0 billion in 2025, then fell by 0.47% to $1.0 billion in 2026.
• Business Quant data shows KRYS's Current Assets at $1.0 billion in Q1 2026, $1.0 billion in Q4 2025, and $925.6 million in Q3 2025.